Antithrombotic therapy in patients after valve surgery with special attention to the combination of anticoagulant and antiplatelet therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10189286" target="_blank" >RIV/00179906:_____/13:10189286 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/13:10189286

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0010865013000118#" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0010865013000118#</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2013.01.009" target="_blank" >10.1016/j.crvasa.2013.01.009</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Antithrombotic therapy in patients after valve surgery with special attention to the combination of anticoagulant and antiplatelet therapy

Popis výsledku v původním jazyce

Patients after implantation of mechanical valves need life-long anticoagulant therapy. Nearly 30% of these patients have also indication for antiplatelet therapy because of concomitant ischemic heart disease or peripheral arterial disease. Combined anticoagulant and dual antiplatelet therapy (so called triple therapy - aspirin, clopidogrel and vitamin K antagonists) is indicated in patients with acute coronary syndrome and after percutaneous coronary intervention (PCI) for a different time according tothe type of stent used during the procedure. Triple therapy is substantially more efficacious in reducing the occurrence of cardiovascular events and mortality in patients undergoing PCI with an indication for long-term anticoagulant therapy, compared with dual antiplatelet therapy. On the other hand it carries 3.5 to 4 times higher risk of bleeding in treated patients. Recently new anticoagulants (dabigatran, rivaroxaban, apixaban) and antiplatelet drugs (prasugrel and ticagrelor) came

Název v anglickém jazyce

Antithrombotic therapy in patients after valve surgery with special attention to the combination of anticoagulant and antiplatelet therapy

Popis výsledku anglicky

Patients after implantation of mechanical valves need life-long anticoagulant therapy. Nearly 30% of these patients have also indication for antiplatelet therapy because of concomitant ischemic heart disease or peripheral arterial disease. Combined anticoagulant and dual antiplatelet therapy (so called triple therapy - aspirin, clopidogrel and vitamin K antagonists) is indicated in patients with acute coronary syndrome and after percutaneous coronary intervention (PCI) for a different time according tothe type of stent used during the procedure. Triple therapy is substantially more efficacious in reducing the occurrence of cardiovascular events and mortality in patients undergoing PCI with an indication for long-term anticoagulant therapy, compared with dual antiplatelet therapy. On the other hand it carries 3.5 to 4 times higher risk of bleeding in treated patients. Recently new anticoagulants (dabigatran, rivaroxaban, apixaban) and antiplatelet drugs (prasugrel and ticagrelor) came

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

"e164"-"e169"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—